Bullous erythema multiforme following topical diphenylcyclopropenone application

Oh, Chang-Wug; Han, K. D.; Kim, Tae‐Heung

doi:10.1111/j.1600-0536.1998.tb05717.x

Cited by 9 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Local blistering and swelling, 42,49 , 101 pompholyx‐like eruptions, 65,102 passive transfer of the sensitizer causing eczema distant from the application site 42,43,64,65,68,71,103 and regional lymphadenopathy 36,62 , 65,89 , 90,101 are common. Erythema multiforme‐like reactions, 49,60 , 62,104–108 fever, 92 palpitations, 73 flu‐like symptoms 65,94 and headache 49,69 are infrequent. Vitiligo 60,62 , 75–80,92 , 109 occurs in about 7% of patients treated, similar to the 4–9% incidence of vitiligo in untreated AA.…”

Section: Introductionmentioning

confidence: 99%

The therapeutic use of topical contact sensitizers in benign dermatoses

Buckley

Vivier

2008

British Journal of Dermatology

View full text Add to dashboard Cite

Topical therapy using contact sensitizers has been practised since the 1960s to treat conditions associated with an altered immunological state. Dinitrochlorobenzene, squaric acid dibutyl ester and diphencyprone are most commonly employed in the therapy of alopecia areata and viral warts. Few dermatology departments in the U.K. provide such treatment. This systematic review discusses the various contact sensitizers used for topical immunotherapy, the methodology of treatment, factors influencing efficacy and likely adverse effects.

show abstract

Section: Introductionmentioning

confidence: 99%

The therapeutic use of topical contact sensitizers in benign dermatoses

Buckley

Vivier

2008

British Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Except for the expected adverse reactions, that is, contact dermatitis [148,[163][164][165] or lymphadenopathy [166][167][168], there are some rare or even serious adverse events reported. These include urticaria [169][170][171][172][173][174][175][176][177], depigmentation [155,156,160], vitiligo [150-154, 157-159, 178], erythema multiforme [179][180][181][182][183], discoid lupus erythematosus [184,185], angioedema [186,187], nickel sensitivity [188], allergic contact dermatitis from dyes in wigs [189], acquired hair curling [190], hair pigmentary changes [191], psoriatic koebnerization [192], pityriasis lichenoides [193], dyspepsia [173], epidermolysis bullosa acquisita [194], and anaphylaxis [195]. In addition, there are a few reports documenting sensitization to the medical staff that handle the chemical compound [196][197][198][199][200][201].…”

Section: Adverse Effects and Safety Concerns Of Topical Immunotherapymentioning

confidence: 99%

Use of Contact Immunotherapy in the Treatment of Skin Diseases Other than Alopecia Areata

Lai

Tsai

2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

For decades, contact immunotherapy with dinitrochlorobenzene, diphencyprone, and squaric acid dibutylester has played an important role in both clinical practice and scientific research. It is listed as the first-line treatment for extensive alopecia areata and was more recently approved for melanoma treatment as an orphan drug in the USA. Moreover, owing to the relative low cost and safety, topical immunotherapy has also been used in many infectious, neoplastic, and inflammatory dermatological diseases. It is especially valuable in vulnerable groups, for cosmetic/pain sensitive areas, or for multiple lesions. In this review, we summarize the current evidence supporting the use of contact immunotherapy for treatment of skin diseases, from articles collected from PubMed database. Owing to space limitation and already numerous studies focusing on alopecia areata, we include only skin diseases other than alopecia areata. In addition to diseases that have been reported to be treated by contact immunotherapy, the hypothesized mechanism, prognosis prediction, efficacy, and safety of these topical agents are discussed.

show abstract

“…Cervical lymphadenopathy is universal 28,60,67,69,71 . Erythema multiforme‐like reactions, 9,21,60,125‐128 fever, 68 flu‐like symptoms 73 and headache 9,57 are infrequent. Vitiligo 21,60,65,68,114‐119 is a hazard, especially in patients of darker complexions, and it is recommended that extreme caution should be exercised in treating patients with dark skin 28 .…”

Section: Side‐effectsmentioning

confidence: 99%

Topical Immunotherapy in Dermatology

Buckley

Vivier

1999

Int J Clinical Practice

View full text Add to dashboard Cite

SUMMARYTopical immunotherapy of skin diseases has been used since the 1970s to treat conditions thought to result from an altered immunological state, mainly extensive alopecia areata and resistant viral warts. Despite its effectiveness, only a handful of dermatology departments in the UK currently provide such treatment. Any of three universal contact sensitisers may be used for topical immunotherapy; but diphencyprone (DCP) has advantages over dinitrochlorobenzene (DNCB) and squaric acid dibutyl ester (SADBE). Sensitisation of medical, nursing and pharmacy staff may be avoided by careful handling of the solutions. Local blistering and eczematous eruptions are the most common risks in patients undergoing treatment; vitiligo and erythema multiforme‐like reactions are rare complications. Topical immunotherapy using DCP with close supervision is a useful option for severe alopecia areata and resistant viral warts.

show abstract

Bullous erythema multiforme following topical diphenylcyclopropenone application

Cited by 9 publications

References 9 publications

The therapeutic use of topical contact sensitizers in benign dermatoses

The therapeutic use of topical contact sensitizers in benign dermatoses

Use of Contact Immunotherapy in the Treatment of Skin Diseases Other than Alopecia Areata

Topical Immunotherapy in Dermatology

Contact Info

Product

Resources

About